JamieDWeismanMD

Dermatology • Atlanta, GA

Dermatologist at Medical Dermatology Specialists, Inc.

Join to view full profile

Dr. Weisman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weisman's full profile

Already have an account?

Office
5730 Glenridge Dr
Ste T100
Atlanta, GA 30328
Phone+1 404-939-9220

Fax+1 404-939-9221

Education & Training

Emory University School of MedicineResidency, Dermatology, 1999 - 2002
Emory University School of MedicineClass of 1998

Certifications & Licensure

GA State Medical License 2001 - 2025
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2011-2013

Clinical Trials

Vascular Inflammation in Psoriasis Trial (The VIP Trial) Start of enrollment: 2012 Jul 01
Completed
Phase 4
Vascular Inflammation in Psoriasis - Extension Study Start of enrollment: 2013 Apr 01
Completed
Phase 4
VPD-737 for Treatment of Chronic Pruritus Start of enrollment: 2013 Oct 15
Completed
Phase 2
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) Start of enrollment: 2014 Jun 16
Completed
Phase 3
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Start of enrollment: 2016 Apr 01
Completed
Phase 3
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28
Completed
Phase 3
A Study of LY3471851 in Participants With Eczema Start of enrollment: 2019 Dec 04
Completed
Phase 1
A Study of LY3471851 in Participants With Psoriasis Start of enrollment: 2019 Nov 26
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

7 citations
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Amy S Paller, Carsten Flohr, Lawrence F Eichenfield, Alan D Irvine, Jamie Weisman
Dermatology and Therapy. 2023-07-01
5 citations
Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data.
Amit Garg, Haley B Naik, Afsaneh Alavi, Paul Hazen, Jennifer L Hsiao
Dermatology and Therapy. 2023-02-01
16 citations
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.
Alexa B Kimball, Christian Loesche, Errol P Prens, Falk G Bechara, Jamie Weisman
Experimental Dermatology. 2022-10-01

Press Mentions

Dr. Matthew Reschly of Medical Dermatology Specialists, Inc. Is Now Seeing Patients at the New Lawrenceville, GA, ClinicJuly 26th, 2022
Atlanta’s Top Docs Share Their Stories of Unexpected, Inspiring, and Memorable CasesJuly 22nd, 2022
Atlanta Medical Dermatology Specialists Welcomes Dr. Aimen Ismail to the TeamJanuary 29th, 2019